NovoCure Limited (NVCR)

Market Cap	1.20B -43.5%
Revenue (ttm)	655.35M +8.3%
Net Income	-136.23M
EPS	-1.22
Shares Out	113.79M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,154,360
Open	10.52
Previous Close	10.55
Day's Range	10.30 - 10.87
52-Week Range	9.82 - 20.06
Beta	0.82
Analysts	Buy
Price Target	28.08 (+166.16%)
Earnings Date	Apr 30, 2026

About NVCR

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Lim...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Oct 2, 2015
• Employees: 1,605
• Stock Exchange: NASDAQ
• Ticker Symbol: NVCR
• Website: https://www.novocure.com

Financial Performance

In 2025, NovoCure's revenue was $655.35 million, an increase of 8.28% compared to the previous year's $605.22 million. Losses were -$136.23 million, -19.21% less than in 2024.

Analyst Summary

According to 6 analysts, the average rating for NVCR stock is "Buy." The 12-month stock price target is $28.08, which is an increase of 166.16% from the latest price.

Price Target

$28.08

(166.16% upside)

Analyst Consensus: Buy